|
Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol , No 15S ( Supplement), :
© 2009 American Society of Clinical Oncology
|
Arm A |
Arm B |
|
| Baseline and post Cycle 4 LVEF (C5D1) available |
93 |
106 |
| Median post Cycle 4 LVEF |
63% |
61% |
| Pts with post Cycle 4 LVEF decline > 10% |
13 (14%) |
7 (7%) |
| Pts with post Cycle 4 drop >10% & LVEF < LLN |
2 |
2 |
| Baseline and post Cycle 8 LVEF (C9D1) available |
81 |
88 |
| Median post Cycle 8 LVEF |
62% |
62% |
| Pts with post Cycle 8 LVEF decline > 10% |
9 (11%) |
8 (9%) |
| Pts with post Cycle 8 drop >10% & LVEF < LLN |
0 |
1 |
|
|
